19Feb 2025
Preclinical Insights on Nelarabine for T-ALL Therapy Improvement

Preclinical Insights on Nelarabine for T-ALL Therapy Improvement

The review critically evaluates the preclinical molecular pharmacology of nelarabine, the only T-cell acute lymphoblastic leukemia (T-ALL) specific drug in clinical use. While nelarabine's active metabolite, ara-G triphosphate, targets nuclear DNA synthesis, unresolved questions remain on its DNA lesions, repair mechanisms, and additional cellular targets. The review emphasizes the need for further research into nelarabine’s combination therapies and future mechanisms for enhancing its efficacy and reducing toxicity in T-ALL treatment.

  • #oncology

Like

Save

Share